Business Wire

American Bureau of Shipping Issues Full Class for Saildrone Surveyor Deep-water, Ocean-going USV

27.8.2025 13:00:00 CEST | Business Wire | Press Release

Share

Saildrone, the global leader in maritime autonomy, today announced that its Surveyor-class of unmanned surface vehicle (USV) has received full classification from the American Bureau of Shipping (ABS). This milestone follows the Voyager, Saildrone’s coastal and near-shore USV, which received ABS class in 2023.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250827715828/en/

The American Bureau of Shipping (ABS) has issued full classification for the Saildrone Surveyor, a 20-meter USV capable of long-endurance missions in the open ocean, collecting deep-ocean bathymetry and performing a wide range of maritime domain awareness tasks—from anti-submarine warfare (ASW) to trans-ocean cable route surveys. This landmark achievement sets a new global benchmark for unmanned systems and highlights Saildrone’s leadership in developing fully classed, open-ocean-capable USVs.

This landmark achievement sets a new global benchmark for unmanned systems and highlights Saildrone’s leadership in developing fully classed, open-ocean-capable USVs.

While other platforms have received certificates or interim approvals under evolving unmanned vessel frameworks, no other USV or UUV has yet received full classification status from any classification society. ABS is the first to grant full class to an unmanned platform, marking a key milestone for the industry.

The classification notation assigned is ✠A1, DV Naval Craft, AUTONOMOUS (NAV, MNV, PRP, AUX, RO3), which follows the “Rules for Building and Classing Light Warships, Patrol, and High-Speed Naval Vessels (2023).”

“The ABS class certification is more than a certificate—it’s a signal to governments and the maritime industry that Saildrone USVs are mature, safe, tested, and ready for scale,” said Richard Jenkins, Saildrone founder and CEO. “It’s been a very large investment and a multi-year process to achieve ABS Class Certification, but we are proud to be the first company in the world to do so and proud that our systems have reached the highest standards as required by the ABS Class certificate.”

ABS class is an internationally recognized standard for safety, design integrity, and operational reliability. The classification process is a rigorous review and validation of a vessel’s design, construction, and autonomous control systems. For unmanned platforms like the Saildrone Surveyor and Saildrone Voyager, this process includes autonomous control systems, cybersecure communications, structural integrity, and fail-safe redundancies, ensuring the vehicle can safely operate without crew, even in complex, unpredictable ocean conditions.

The 20-meter Surveyor is capable of long-endurance missions in the open ocean, collecting deep-ocean bathymetry and performing a wide range of maritime domain awareness tasks—from anti-submarine warfare (ASW) to trans-ocean cable route surveys. The 10-meter Voyager is designed for persistent surveillance in coastal and near-shore environments, complementing the Surveyor’s blue-water capabilities. Both platforms are capable of fully autonomous operations with no humans on board and are remotely monitored 24/7 by Saildrone’s global Mission Management team.

“ABS and Saildrone are pioneering new frontiers, setting the pace for innovation. This step forward is a result of our investments in ABS’s technical capability and helping to ensure our Rules are able to support innovation with an unwavering focus on safety,” said Patrick Ryan, ABS Senior Vice President and Chief Technology Officer.

Saildrone USVs are currently supporting missions around the world, including ocean mapping, border security, persistent ISR, and critical infrastructure security. With both its Surveyor and Voyager platforms fully classed by ABS, Saildrone is uniquely positioned to support the next generation of naval and commercial unmanned operations.

About Saildrone

Saildrone is a defense company delivering maritime intelligence, surveillance, and reconnaissance products to military, homeland security, and commercial customers. Saildrone unmanned surface vehicles (USVs) are extreme-endurance platforms equipped with advanced sensors and proprietary AI to provide persistent insights above and below the sea surface. Insights that support border security, law enforcement, undersea infrastructure protection, hydrography, and naval power applications. With more than 2,000,000 nautical miles sailed and 50,000 days at sea, Saildrone USVs are trusted by governments across the planet and set the standard for cost-efficient maritime intelligence in the world’s harshest environments.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250827715828/en/

Contacts

Jenn Virskus
Director Marketing, Saildrone
Office: (510) 956-8361
jenn.virskus@saildrone.com

(c) 2024 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release

inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and

Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press Release

Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye